ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC lowered its stake in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) by 12.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 51,202 shares of the company’s stock after selling 7,102 shares during the quarter. SG Americas Securities LLC owned about 0.05% of ARS Pharmaceuticals worth $540,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Renaissance Technologies LLC grew its stake in shares of ARS Pharmaceuticals by 884.9% in the 2nd quarter. Renaissance Technologies LLC now owns 124,100 shares of the company’s stock valued at $1,056,000 after purchasing an additional 111,500 shares during the last quarter. The Manufacturers Life Insurance Company acquired a new stake in shares of ARS Pharmaceuticals during the second quarter worth $180,000. Creative Planning grew its position in ARS Pharmaceuticals by 7.0% in the 3rd quarter. Creative Planning now owns 35,263 shares of the company’s stock valued at $511,000 after buying an additional 2,307 shares during the last quarter. nVerses Capital LLC acquired a new position in ARS Pharmaceuticals in the 3rd quarter valued at $30,000. Finally, Raymond James & Associates purchased a new position in ARS Pharmaceuticals during the 3rd quarter worth $2,969,000. Institutional investors and hedge funds own 68.16% of the company’s stock.

ARS Pharmaceuticals Stock Down 8.9 %

Shares of SPRY opened at $13.02 on Friday. ARS Pharmaceuticals, Inc. has a 52-week low of $6.13 and a 52-week high of $18.51. The company has a 50-day simple moving average of $12.50 and a 200-day simple moving average of $13.08. The company has a market capitalization of $1.27 billion, a PE ratio of -25.53 and a beta of 0.96.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. Leerink Partners lifted their target price on shares of ARS Pharmaceuticals from $26.00 to $27.00 and gave the company an “outperform” rating in a report on Monday, January 13th. Raymond James raised their price objective on shares of ARS Pharmaceuticals from $26.00 to $28.00 and gave the company a “strong-buy” rating in a research report on Tuesday, January 14th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $30.00 target price on shares of ARS Pharmaceuticals in a research report on Tuesday, October 8th. Four research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $26.00.

Insiders Place Their Bets

In other ARS Pharmaceuticals news, Director Laura Shawver sold 50,000 shares of the business’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $11.10, for a total transaction of $555,000.00. Following the sale, the director now directly owns 210,346 shares in the company, valued at approximately $2,334,840.60. The trade was a 19.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Brian Dorsey sold 25,000 shares of the company’s stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $12.30, for a total value of $307,500.00. Following the completion of the sale, the chief operating officer now directly owns 6,024 shares in the company, valued at $74,095.20. This trade represents a 80.58 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 1,095,558 shares of company stock worth $16,853,686. 40.10% of the stock is owned by company insiders.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.